substudy

Related by string. * * genetic substudy *

Related by context. All words. (Click for frequent words.) 70 subanalysis 69 retrospective cohort study 69 multicenter study 68 multicenter randomized controlled 68 prospective observational 68 subgroup analyzes 67 CARE HF 67 Prostate Lung Colorectal 67 multicentre randomized 67 observational cohort study 67 prospective cohort 67 nonrandomized 67 ONTARGET 66 phase IIIb 66 Carotid Revascularization Endarterectomy vs. 66 Digital Mammographic Imaging 66 WHIMS 66 VADT 66 placebo controlled clinical 66 ASTEROID 66 randomized clinical 65 Intervention Trial 65 RE LY trial 65 ACCOMPLISH 65 Multi Ethnic Study 65 multicenter prospective 65 randomized multicenter 65 ARBITER 6 65 prospective randomized controlled 65 HORIZONS AMI trial 65 randomized controlled trial 65 TMC# C# 65 STRIDE PD 65 multicenter 65 prospective multicenter 65 RE LY 65 retrospective cohort 64 ExTRACT TIMI 64 PROVE IT 64 SABCS 64 prospective multicentre 64 Thrombolysis 64 CHAMPION PCI 64 Prospective Randomized 64 ACUITY trial 64 multicenter randomized 64 Clinical Antipsychotic Trials 64 retrospective observational study 64 PRECISE 64 periprocedural MI 64 RE LY ® 64 observational study 63 longitudinal observational study 63 CALGB 63 multicentre 63 longitudinal cohort study 63 PROactive study 63 Aggressive Reduction 63 REGARDS 63 Screening Trial 63 MEND CABG 63 AIM HIGH 63 Subgroup analyzes 63 double blinded randomized 63 multicenter phase 63 ENDEAVOR IV 63 prospectively randomized 63 multicentre study 63 multicenter clinical 63 Screening Trial DMIST 63 placebo controlled Phase III 63 randomized multicenter trial 62 EVEREST II 62 fosbretabulin 62 multicenter randomized clinical 62 HCV SPRINT 62 placebo controlled trials 62 CHAMPION PLATFORM 62 Atherosclerosis MESA 62 Intervention Effectiveness 62 randomized controlled clinical 62 NATRECOR ® 62 HeFT 62 SCD HeFT 62 prospective multicenter study 62 Multiethnic Study 62 PERSEUS 62 randomized controlled 62 PLCO 62 multicenter trials 62 prospective nonrandomized 62 Phase III randomized 62 multicentre prospective 62 SYNTAX trial 62 multicentre randomized double 61 Intervention Effectiveness CATIE 61 MIST II 61 Intervention Trial GAIT 61 NCT# ClinicalTrials.gov 61 GOUT 61 viral kinetic 61 Subgroup analysis 61 Multicenter 61 APEX AMI trial 61 Kaplan Meier analysis 61 SPIRIT FIRST 61 EURIDIS 61 prospectively defined 61 Edge STudy 61 COPERNICUS 61 multicenter Phase II 61 prospective longitudinal 61 randomized multicenter Phase III 61 BARI 2D 61 ILLUSTRATE 61 EINSTEIN DVT 61 International Verapamil SR 61 placebo controlled randomized 61 prospective randomized multicenter 61 pharmacokinetic PK 61 Acute Myocardial Infarction 61 Trandolapril 61 BRIM3 61 EchoCRT 61 riociguat 61 Glucosamine Chondroitin Arthritis 61 multicenter randomized double 61 PRECiSE 61 Multicentre 61 HYVET 61 Observational Study 61 BOLDER II 61 Randomized controlled 61 NSABP B 61 randomized Phase III 61 sirolimus eluting stents 61 Phase 2a trial 61 CIMZIA TM certolizumab pegol 61 FDG-PET/CT 61 Phase IIIb study 61 gadolinium enhanced 60 Phase Ib clinical 60 landmark ATHENA 60 cerebral microbleeds 60 Framingham Offspring Study 60 Myocardial Infarction Study 60 HOPE TOO 60 ToGA 60 placebo controlled Phase 60 PFO migraine 60 ABCSG 60 randomized Phase IIb 60 prostate cancer PCa 60 phase IIb clinical 60 Evaluation WISE 60 phase IIb study 60 Randomized Evaluation 60 Swedish Mammography Cohort 60 Phase IIIb 60 Stenting Trial CREST 60 placebo controlled studies 60 MADIT II 60 NHANES III 60 nab paclitaxel 60 CURRENT OASIS 7 60 APPRAISE 60 phase IIa 60 Prospective Multicenter 60 EORTC 60 IMPROVE IT 60 BCIRG 60 Prostate Cancer Prevention 60 Myocardial Infarction 60 REALITY Trial 60 multicenter placebo controlled 60 meta analysis 60 Clinical Outcomes Utilizing Revascularization 60 prospective randomized 60 fluvastatin 60 pharmacodynamic effects 60 paclitaxel eluting stents 60 TRITON TIMI 60 randomized blinded 60 multicenter randomized placebo controlled 60 multicentric 60 Phase 1b trial 60 TG MV 60 Gastrointestinal Cancers Symposium 60 Cholesterol Levels SPARCL 60 BOLDER 60 neoadjuvant 60 prospective observational cohort 60 Infarct 60 NEVO RES 60 UKPDS 60 ECASS 59 placebo controlled 59 AACR San Antonio 59 ATACAND 59 multicenter multinational 59 PREVAIL 59 ALLHAT 59 Phase IIB 59 SWOG 59 Polyp Prevention Trial 59 randomized placebo controlled 59 immunohistochemical analysis 59 Communities ARIC study 59 BR.# 59 Ovarian PLCO Cancer 59 Phase III randomized controlled 59 randomized multicentre 59 corrected QT interval 59 Communities ARIC Study 59 randomized 59 Phase 2b study 59 MADIT 59 ACRIN 59 dose escalation Phase 59 desvenlafaxine succinate 59 CATIE AD 59 eptifibatide 59 undergone radical prostatectomy 59 ELCAP 59 ANCHOR trial 59 CAMMS# 59 CARDIA study 59 CARDIA 59 Controlled Trial 59 RADIANT 59 STICH 59 AIR CF1 59 SYNTAX 59 HGPIN 59 randomized controlled trials 59 MERLIN TIMI 59 histologically confirmed 59 ASSERT 59 Sorafenib HCC Assessment 59 Percutaneous Coronary Intervention 59 XIENCE V Stent System 59 PRoFESS 59 randomized controlled multicenter 59 HF ACTION 59 Randomised Study 59 NCCTG 59 rosuvastatin #mg 59 ENDEAVOR III 59 WHEL 59 SPARCL 59 postmenopausal women 59 EBUS FNA 59 Endovascular Valve Edge 59 Secondary efficacy endpoints 59 observational cohort 59 trial evaluating PRX# 59 Sequenced Treatment Alternatives 59 LUX Lung 59 LHRH receptor positive 59 NICE SUGAR 59 recurrent glioblastoma multiforme 59 pT2 59 TAXUS IV 59 AVADO 58 prostate cancer CaP 58 phase IIb trial 58 Randomized Study 58 ACTIVE W 58 prospective multicenter randomized 58 #p# [003] 58 MGd 58 multivariate analyzes 58 SPIRIT III 58 underwent resection 58 Baltimore Longitudinal Study 58 Multicenter AIDS 58 Stenting Trial 58 symptomatic VTE 58 ADMIRE HF 58 Women Ischemia Syndrome 58 randomized crossover 58 Netherlands Cohort Study 58 AIR2 Trial 58 LV dysfunction 58 F FDG PET 58 PREVENT IV 58 PARTNER Trial 58 FDG PET imaging 58 AVERROES 58 HPTN 58 Atherosclerosis Risk 58 Tanespimycin 58 Health Initiative WHI 58 ASCO GU 58 MADIT CRT trial 58 noninferiority 58 Acute Ischemic Stroke 58 PCI ExTRACT TIMI 58 carotid artery stenting CAS 58 BRIM2 58 DAPT 58 Phase IIIb clinical 58 treatment naive genotype 58 clinical pharmacology studies 58 CLL8 58 multicenter Phase 58 Val HeFT 58 Univariate analysis 58 LUMINATE 58 relapsed MM 58 number NCT# ClinicalTrials.gov 58 dose escalation clinical 58 tipranavir r 58 ILLUMINATE 58 APTIVUS 58 trials RCTs 58 HCV RESPOND 2 58 anti arrhythmic drug 58 randomized clinical trials 58 ischemic cardiomyopathy 58 CABANA 58 ZACTIMA 58 meta regression 58 REVIVE 58 XIENCE V PROMUS Stent 58 Randomized Phase 58 adenoma recurrence 58 TAXUS ATLAS 58 NO# [002] 58 FOLPI 58 randomized trials 58 Wisconsin Sleep Cohort 58 RECORD1 58 Heart Failure Trial 58 Phase 1a clinical 58 NMIBC 58 ACCORD Lipid 58 nondiabetic patients 58 bone scintigraphy 58 CAUTIONS 58 Angiographic 58 unstable angina UA 58 II Clinical Trial 58 antiretroviral naïve 58 ASCEND HF 58 recurrent GBM 58 ACCLAIM 58 Echocardiographic 58 plasma pharmacokinetics 58 liver transplant recipients 58 GISSI HF 58 MERIT ES 58 echocardiographic 58 STEP BD 58 Acute Decompensated Heart Failure 58 echocardiographic parameters 58 everolimus eluting stents 58 EmbraceAC 57 #F FDG PET 57 Dialysis Outcomes 57 PRIMO CABG 57 ADVANCE PD 57 TRANSFORMS 57 genotypic resistance 57 randomized controlled Phase 57 Liraglutide Effect 57 Prostate AdenoCarcinoma Treatment 57 radical cystectomy 57 prognostic indicators 57 ConclusionThis 57 label multicenter 57 angiographically 57 colorectal adenoma 57 STENT 57 Left Ventricular Dysfunction 57 REVIVE Diabetes 57 ug dose 57 GISSI 57 interferon gamma 1b 57 Prospective Randomized Trial 57 TAXUS VI 57 Endarterectomy 57 Degarelix 57 neratinib 57 FDG PET 57 REACH Registry 57 relapsed ALL 57 pertuzumab 57 Phase 1b clinical 57 cancer mCRC 57 Primary endpoints 57 phase IIb 57 Randomized Controlled 57 lintuzumab 57 BPS IC 57 bosentan 57 Group RTOG 57 retrospectively analyzed 57 secondary efficacy endpoints 57 COPAXONE R 57 irbesartan 57 multicenter Phase III 57 Ovarian Cancer Screening 57 pharmacokinetics PK 57 assessing T DM1 57 PROSTVAC TM 57 phase IIa clinical 57 blind randomized 57 mildly symptomatic 57 MAGE A3 ASCI 57 florbetaben 57 phase Ib 57 brivaracetam 57 RIO Lipids 57 placebo controlled clinical trials 57 Phase 2b clinical 57 Phase IIb III 57 lipid lowering therapy 57 morphometric vertebral fractures 57 ROCKET AF 57 FDG PET scans 57 CC genotype 57 metaanalysis 57 ATTRACT 57 Thromboembolism 57 XIENCE V demonstrated 57 label multicenter randomized 57 androgen suppression 57 postmenopausal osteoporotic women 57 cardiac magnetic resonance 57 Surgical Treatment 57 blinded randomized 57 DMIST 57 multiple logistic regression 57 gene polymorphism 57 Lp PLA 2 57 sirolimus eluting 57 CUSTOM II 57 SYMMETRY trial 57 Multivariate analysis 57 immunohistochemical 57 PLCO trial 57 patientswith 57 β blockers 57 Ranolazine 57 CHARM Added 57 premenopausal women 57 Logistic regression 57 CLARITY TIMI 57 GAMMAGARD 57 Phase 2a clinical 57 TAXUS V 57 cilostazol 57 Meta Analysis 57 nonfatal MI 57 rs# [004] 57 blind multicenter 57 NSABP 57 adrenalectomy 57 univariate 57 obese postmenopausal 57 ABCB1 57 Aggressive Drug Evaluation 57 CaPSURE 57 genetic polymorphisms 57 Unstable Angina 57 Acute Coronary Syndrome 57 glatiramer acetate 57 dietary questionnaires 57 UNLOAD 57 RRMS patients 57 Randomised 57 multivariable analysis 57 iPrEx study 56 APTIVUS r 56 gefitinib Iressa 56 HALTS 56 HER2 expression 56 ABSORB trial 56 patients undergoing CABG 56 CYPHER Stent 56 recurrent malignant glioma 56 Histopathological 56 TAXUS ARRIVE 56 registrational Phase 56 double blinded placebo 56 hyperintense lesions 56 crizotinib PF # 56 randomized controlled trials RCTs 56 symptomatic BPH 56 Meta analyzes 56 Gynecologic Oncology Group 56 DXA scan 56 immunohistochemical staining 56 Phase 2b trial 56 ENDEAVOR clinical 56 EVA 3S 56 SPIRIT IV 56 metabolic parameters 56 EDEMA3 56 bowel capsule endoscopy 56 nulliparous women 56 undergoing coronary angiography 56 Alpha Tocopherol Beta Carotene 56 Fracture Intervention Trial 56 beta blocker therapy 56 ER CHOP 56 subclinical hypothyroidism 56 lipid lowering drugs 56 MVA MUC1 IL2 56 candesartan cilexetil 56 Patency 56 active comparator 56 scintigraphic 56 Spine Patient Outcomes 56 Randomized trials 56 Folfox 56 selenium supplementation 56 ICON7 56 HIV HCV coinfected 56 Vascugel ® 56 biliary tract cancer 56 RTOG 56 CRESTOR #mg 56 strontium ranelate 56 DES implantation 56 galiximab 56 INTERHEART study 56 Alzheimer Disease Cooperative 56 epidemiologic studies 56 observational studies 56 nonmetastatic 56 blind randomized controlled 56 Dietary Modification Trial 56 carotid IMT 56 QTc 56 TROPIC 56 chest radiographs 56 Histopathologic 56 histologically proven 56 prospective randomized placebo 56 MADIT CRT 56 patients undergoing percutaneous 56 IMPROVE HF 56 Phase IIb clinical 56 Acute Coronary Syndromes 56 ZD# [001] 56 multicentre randomized controlled 56 comparator arm 56 NATRECOR R 56 randomizing patients 56 ID NCT# 56 iPrEx 56 Phase IIa trial 56 logistic regression analysis 56 ezetimibe simvastatin 56 Sipuleucel T 56 sipuleucel T 56 CORD II 56 QLT# 56 Pharmacokinetic 56 liposomal amphotericin B 56 RCTs 56 Genitourinary Cancers Symposium 56 normotensive 56 neurologic progression 56 label multicenter Phase 56 post hoc 56 AREDS 56 Vertos II 56 covariate 56 prucalopride 56 afatinib 56 Platelet Inhibition 56 Enzastaurin 56 confirmatory clinical 56 actigraphy 56 Kaplan Meier curve 56 Cardiac Allograft Rejection 56 valvulopathy 56 logistic regression models 56 univariate analyzes 56 ENGAGE AF TIMI 56 pegylated liposomal doxorubicin 56 Trofex 56 atherosclerotic renal artery stenosis 56 bazedoxifene conjugated estrogens 56 SWiTCH 56 Framingham Offspring 56 clinical trial 56 blinded randomized placebo controlled 56 ENESTnd 56 pharmacodynamic PD 56 CLIRS 56 antioxidant supplementation 56 Phase III VISTA 56 prognostic significance 56 APEX PD 56 Celecoxib APC trial 56 Pharmacokinetics PK 56 Phase 2b Study 56 carotid plaque 56 thyrotropin levels 56 thorough QT 56 CLARITY study 56 Protelos R 56 hip BMD 56 epoetin alpha 56 oral ibandronate 56 GRAVITAS trial 56 preoperative chemotherapy 56 Metastatic Melanoma 56 NAVIGATOR 56 advanced adenoma 56 CAPRIE 56 Safinamide 56 headache nasopharyngitis 56 TIMI 56 antiarrhythmic drug 56 PCa 56 QD dosing 56 Memory Study WHIMS 56 abnormal cytology 56 CTRC AACR San Antonio 56 pegylated interferon alfa 2b 56 SUCCEED trial 56 Antiviral Therapy 56 ASCO GI 56 recurrent glioma 56 timepoint 56 perioperative complications 56 mg/m2 cohort 56 lymphadenectomy 56 OPT CHF 56 neoadjuvant treatment 56 SIMPADICO 56 zotarolimus eluting stent 56 T1a 56 SORT OUT III 56 prognostic variables 56 Study AREDS 56 fallopian tube cancers 56 teriflunomide 56 randomized discontinuation trial 55 CELLO 55 Pharmacokinetic PK 55 reboxetine 55 abciximab 55 ATTAIN 55 atherothrombotic disease 55 everolimus eluting stent 55 carotid endarterectomy CEA 55 chromosome #p# [002] 55 NSTE ACS 55 ELACYT 55 BRCA mutation carriers 55 elotuzumab 55 Pre RELAX AHF 55 Phase 1b 55 thromboembolic 55 CATIE 55 XELOX 55 Phase III multicenter 55 Randomized Controlled Trials 55 oral FTY# 55 KRAS status 55 IL#B 55 stage IIIB 55 polyarticular 55 sunitinib malate 55 PEG IFN 55 evaluating tivozanib 55 Multivariate logistic regression 55 recurrent metastatic 55 Doxil ® 55 Temsirolimus 55 antiretroviral naive 55 Oral Fingolimod 55 ataluren 55 prospective observational studies 55 noninferior 55 polysomnogram 55 coronary stenosis 55 hormone receptor negative 55 PRADAXA 55 composite endpoint 55 preclinical pharmacokinetic 55 TIMP 1 55 Atherosclerotic 55 Phase Ib II 55 ASCUS 55 ARCOXIA 55 Phase 2b 55 transthoracic 55 T2 lesions 55 LEXIVA r 55 randomized double 55 ARIXTRA 55 definite stent thrombosis 55 Ambulatory Blood Pressure 55 RSD# oral 55 Phase IIb trial 55 breast carcinoma 55 Phase III Clinical Trial 55 mg BID dose 55 cisplatin vinorelbine 55 perfusion defects 55 Histologic 55 Pivotal Clinical Trial 55 CAVEATS 55 Fondaparinux 55 Preclinical Study 55 ximelagatran 55 PSN# [002] 55 Histological 55 IPAH 55 logistic regression model 55 phase 2a 55 KRN# 55 multivariate Cox 55 EQUIP OB 55 mammographic density 55 DEFER 55 duplex ultrasonography 55 recurrent venous thromboembolism 55 eplerenone 55 HRCT 55 Clinicaltrials.gov 55 estramustine 55 overnight polysomnography 55 Study Evaluating 55 bivariate analyzes 55 Carotid 55 eculizumab therapy 55 registrational 55 clinico pathological 55 flutamide 55 olaparib 55 PROTECT AF 55 CALGB # [001] 55 ibandronate 55 attain statistical significance 55 Feasibility Trial 55 Rosuvastatin 55 Dual Antiplatelet Therapy 55 singleton pregnancies 55 lorcaserin Phase 55 transrectal ultrasound guided 55 biochemical relapse 55 CALGB # [002] 55 tumor histology 55 AVOREN 55 IIIa inhibitor 55 sorafenib Nexavar 55 carotid artery stenting 55 computed tomographic 55 thiazolidinediones TZDs 55 FASLODEX 55 ST Segment Elevation 55 Long Lesion 55 study1 55 Bone Mineral Density 55 INSPIRE Trial Phase III 55 secondary efficacy endpoint 55 lacunar 55 multivariate logistic regression 55 visceral metastases 55 pivotal bioequivalence 55 carotid atherosclerosis 55 unfractionated heparin UFH 55 Phase 2b Clinical Trial 55 BZA CE 55 NLX P# 55 dose atorvastatin 55 PRE SURGE 55 CYPHER R Sirolimus eluting 55 Elocalcitol 55 Metabolic Efficiency 55 Estrogen Receptor 55 Registry NOPR 55 ENVISION 55 underwent coronary angiography 55 Ischemic 55 dual endothelin receptor antagonist 55 adjuvant radiotherapy 55 leiomyomas 55 Chronic Heart Failure 55 Randomized Controlled Trial 55 Asymptomatic 55 Zenvia Phase III 55 tanespimycin 55 RENAL 55 operable breast cancer 55 Trial PCPT 55 transthoracic echocardiography 55 TLK# 55 postoperative AF 55 CONFIRM 55 arthrography 55 Subarachnoid hemorrhage 55 pain palliation 55 Systemic Sclerosis 55 multivariable adjusted 55 Resynchronization 55 postintervention 55 BENICAR HCT 55 ABC/3TC 55 papillary renal cell carcinoma 55 squamous histology 55 Pharmacodynamic 55 Nutrition EPIC 55 Phase III clinical 55 EDEMA4 55 secondary endpoint 55 recurrent VTE 55 NCCTG N# 55 Acute Coronary Syndromes ACS 55 cediranib 55 EOquin TM 55 pharmacokinetic PK study 55 treatment naïve genotype 55 Trial NLST 55 Drug Eluting Stents 55 mg/m2 dose 55 Abciximab 55 lumbar spine BMD 55 ritonavir boosted 55 Phase Ib study 55 rosuvastatin 55 clinicopathological 55 prespecified secondary 55 efficacy endpoint 55 metastatic HRPC 55 DEXA scan 55 tarenflurbil 55 Xelox 55 NEVO 55 CIMZIA ™ 55 Phase 1a 55 ISAR REACT 55 stage IIIb IV 55 Pharmacokinetic studies 55 Systolic Blood Pressure 55 beta carotene supplementation 55 T2DM 55 masked placebo controlled 55 dyslipidaemia 55 nonischemic 55 NHANES 55 evaluable subjects 55 serum estradiol 55 linear regression analyzes 55 Neoadjuvant 55 oral diclofenac 55 pan HDAC inhibitor 55 mixed hyperlipidemia 55 longitudinal study 55 transvaginal sonography 55 Multicenter Study 55 dose dose escalation 55 ADAS Cog 55 logistic regression analyzes 55 MIVI TRUST 55 Multicenter Automatic Defibrillator Implantation 55 mITT population 55 GRNCM1 55 cortical stimulation 55 hemodynamically significant 55 perfusion abnormalities 55 landmark ATHENA trial 55 viral kinetics 55 Initiated Phase 55 CTEPH 55 Coronary Artery Bypass Graft 55 dosing cohort 55 intraobserver 55 biochemical recurrence 55 preoperative MRI 55 cardiovascular morbidity 55 Amrubicin 55 MR spectroscopy 55 Angiogram 55 blinded placebo controlled 55 mCRC patients 55 TAXUS Express Stent 55 QRS interval 54 Kaplan Meier curves 54 Bivalirudin 54 pCR 54 MTWA testing 54 RG# [001] 54 SNP rs# [002] 54 urolithiasis 54 histopathological 54 Multiple Ascending Dose 54 NEVO ™ 54 controlled multicenter 54 placebo controlled dose escalation 54 doxorubicin docetaxel 54 IMPACT DCM 54 clopidogrel pretreatment 54 Study HERS 54 Group ECOG 54 bi ventricular pacing 54 Relieve Depression 54 Scandinavian Simvastatin Survival 54 LV ejection fraction 54 arzoxifene 54 genomewide association study 54 Endometrial 54 Randomized Clinical Trial 54 intact parathyroid hormone 54 extensive metabolizers 54 minimally symptomatic 54 conjugated equine estrogen 54 paricalcitol 54 reflux esophagitis 54 cardioprotective effects 54 AIR CF2 54 mutated K ras 54 Logistic regression analysis 54 Tumor Response 54 See CLINICAL PHARMACOLOGY 54 Immunohistochemical analysis 54 arteriography 54 coinfected patients 54 #:#-# [031] 54 transabdominal 54 PEARL SC 54 Radiation Therapy Oncology 54 Intra operative 54 thrombus aspiration 54 Phase III placebo controlled 54 Phase IIa trials 54 retinal vein occlusion induced 54 Epidemiologic studies 54 study 54 chronic thromboembolic pulmonary 54 melphalan prednisone 54 STICH trial 54 Lipid Lowering Treatment 54 retaspimycin 54 INCB# [003] 54 ADAGIO study 54 skin sterol 54 tirofiban 54 Plain radiographs 54 sonographic findings 54 adjuvant tamoxifen 54 TDF FTC 54 varespladib 54 Peripheral Arterial 54 Univariate 54 ASBMR 54 BERKELEY CA UroToday.com 54 Angiox R 54 Motesanib 54 Alzheimer Disease Neuroimaging Initiative 54 inflammatory biomarkers 54 ischemic lesions 54 TASQ 54 CRLX# 54 nonvertebral fracture 54 Phase IIa clinical 54 NSABP C 54 IL# PE#QQR 54 MDRD 54 EDEMA3 trial 54 ANCOVA 54 adjuvant chemotherapy 54 Systolic Hypertension 54 Ranibizumab 54 AOD# [002] 54 evaluating carfilzomib 54 Placebo Controlled Trial 54 Long Term Efficacy 54 serum markers 54 blind placebo controlled 54 FDA defined valvulopathy 54 intima media thickness 54 Phase Ib Clinical Trial 54 double blind placebo 54 COMFORT II 54 POISE 54 evaluating Actimmune 54 intravesical therapy 54 #rd Annual CTRC 54 registrational trial 54 TRANSCEND 54 Endeavor Resolute DES 54 vitro experiments 54 CR nPR 54 goserelin 54 COPAXONE ® 54 liver resection 54 Clinical Outcome 54 Pivotal Trial 54 femoral neck BMD 54 tibolone

Back to home page